Significant market potential seen for Trius Therapeutics' phase III candidate Print E-mail
By Staff and Wire Reports   
Tuesday, 25 January 2011 13:23
best penny stock picksJason Napodano, CFA of Zacks investment research has initiated coverage of Trius Therapeutics (Nasdaq:TSRX) with an Outperform rating and $10 price target.

"We believe in the company’s phase III candidate, Torezolid, for acute bacterial skin and skin structure infections (ABSSSI) and methicillin-resistant Staphylococcus aureus (MRSA," writes Napodano. "We see Torezolid as having significant market potential based on a clear superior profile to the two market-leading products in Pfizer’s Zyvox (linezolid) and Cubist’s Cubicin (daptomycin). Torezolid offers rapid efficacy onset, convenient once-daily dosing, a short course of therapy, and powerful efficacy. Pfizer’s Zyvox will post worldwide sales over $1.1 billion in 2010 despite its limitations. We believe that Trius’ phase III program will prove that 6 once daily 200mg Torezolid pills are superior to 10 twice-daily (20 total) 600mg Zyvox pills.

"Once approved, we believe the market will rapidly convert to Trius’ Torezolid product. There is clear precedence that backs-up our belief. The market rapidly shifted from generic vancomycin to the more effective Zyvox a decade ago, and newer products such as Cubicin and Tygacil are gaining share on Zyvox now. Assuming FDA and EMEA approvals in 2015, we are modeling Torezolid worldwide sales of $750 million by 2020. Assuming Trius seeks to commercialize Torezolid in the U.S. on its own and partners in EU, we see net income in 2020 of $230 million, with EPS of $5.75. Based on our discounted cash flow (DCF) analysis, we see Trius fairly valued at market capitalization of roughly $250 to $275 million based on these projections."

"Finally, on a simple comparison to its peers, Trius looks vastly undervalued. The two closes competitors are Cubist Pharmaceuticals and Optimer Pharmaceuticals. Cubist has a market capitalization of nearly $900 million. Optimer has a market capitalization of nearly $450 million. We see Trius following down the same path as these two companies, only several years behind. The current market capitalization of Trius at just shy of $100 million significantly discounts the company's future potential.

"We have concluded that a market capitalization of $250 million is fair for Trius based on the potential best-in-class characteristics of Torezolid. This equates to a price target of $10 per share. Our rating is Outperform.

Jason's new report for Trius from Zaxks Investment Research is now available for download:

http://biomedreports.com/Stock-Research-Reports/View-category.html?dir=DESC&limit=20&limitstart=0&order=date




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter